Naloxegol for opioid- induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387-2396.Chey WD, Webster L,Sostek M,et al. Naloxegol for opioid-induced constipation in patients with noncancer pain[J].New England Journal of Medicine,2014,370(25) :2387 ...
Naloxegol approved for opioid-induced constipation The US FDA has approved naloxegol (MOVANTIK) for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, according to an AstraZeneca media release. It is expected to be available to patients in the fi... None...
placebo-controlled phase 3 trials They enrolled outpatients aged 18 to 84 years who had been taking an oral opioid for noncancer pain, at a stable total daily dose of 30 to 1000 mg of morphine or equivalent for at least 4 weeks, and had confirmed opioid-induced constipation. ...
Naloxegolisindicatedforthetreatmentofopioid-induced constipation(OIC)inadultpatientswithchronic non-cancerpain. Availableastabletwitheachcontaining25mgor12.5mg ofnaloxegolandtherecommendeddoseis25mgonce dailyinthemorning. The2015worldwidesalesdataofMovantik ...
AstraZeneca has announced positive top-line results from two Phase III trials and one safety extension trial in patients with non-cancer related pain and opioid-induced constipation (OIC). These Phase III KODIAC trials evaluated the safety and efficacy of naloxegol, an oral peripherally-acting, mu...
产品描述Naloxegol, also known as and NKTR-118 and AZ-13337019, is a peripherally-selective opioid antagonist for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Chemically, naloxegol is a pegylated (polyethylene glycol-modified...
Naloxegol oxalate (XXI) is a peripherally acting μ-opioid receptor antagonist that was approved in the USA and EU for the treatment of opioid-induced constipation in adults with chronic non-cancer pain. The drug, a pegylated version of naloxone, has significantly reduced central nervous system (...
Naloxegol is effective in the treatment of opioid-induced constipation, without reducing opioid-mediated analgesia, in patients with chronic non-cancer pain, according to the results of two large phase III studies conducted in the US and Europe. The double-blind, parallel-group, placebo-controlled ...
The US FDA has approved naloxegol (MOVANTIK) for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, according to an AstraZeneca media release. It is expected to be available to patients in the first half of 2015. During the review of the NDA, the ...
Naloxegol is a peripherally acting mu-opioid receptor antagonist (PAMORA) in clinical evaluation for the treatment of OIC. In two phase 3 randomized, double-blind, 12-week studies conducted in outpatients with noncancer pain and OIC (KODIAC-04, n=652 [NCT01309841 ] ; KODIAC-05, n=700 [...